JP7258746B2 - エンベロープウイルスの非遺伝的改変 - Google Patents

エンベロープウイルスの非遺伝的改変 Download PDF

Info

Publication number
JP7258746B2
JP7258746B2 JP2019515292A JP2019515292A JP7258746B2 JP 7258746 B2 JP7258746 B2 JP 7258746B2 JP 2019515292 A JP2019515292 A JP 2019515292A JP 2019515292 A JP2019515292 A JP 2019515292A JP 7258746 B2 JP7258746 B2 JP 7258746B2
Authority
JP
Japan
Prior art keywords
tumor
virus
seq
peptide
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532631A (ja
JP2019532631A5 (enExample
Inventor
セルロ，ビンチェンツォ
カパッソ，クリスチャン
イロスマキー，エルッコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valo Therapeutics Oy
Original Assignee
Valo Therapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valo Therapeutics Oy filed Critical Valo Therapeutics Oy
Publication of JP2019532631A publication Critical patent/JP2019532631A/ja
Publication of JP2019532631A5 publication Critical patent/JP2019532631A5/ja
Priority to JP2022197406A priority Critical patent/JP2023029997A/ja
Application granted granted Critical
Publication of JP7258746B2 publication Critical patent/JP7258746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019515292A 2016-09-27 2017-09-06 エンベロープウイルスの非遺伝的改変 Active JP7258746B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022197406A JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
GB1616365.1 2016-09-27
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022197406A Division JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Publications (3)

Publication Number Publication Date
JP2019532631A JP2019532631A (ja) 2019-11-14
JP2019532631A5 JP2019532631A5 (enExample) 2020-10-08
JP7258746B2 true JP7258746B2 (ja) 2023-04-17

Family

ID=57539741

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515292A Active JP7258746B2 (ja) 2016-09-27 2017-09-06 エンベロープウイルスの非遺伝的改変
JP2022197406A Pending JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022197406A Pending JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Country Status (12)

Country Link
US (1) US10982194B2 (enExample)
EP (1) EP3519565A1 (enExample)
JP (2) JP7258746B2 (enExample)
KR (1) KR102599401B1 (enExample)
CN (1) CN109890957A (enExample)
AU (2) AU2017337753B2 (enExample)
BR (1) BR112019005825A2 (enExample)
CA (1) CA3035104A1 (enExample)
GB (1) GB201616365D0 (enExample)
RU (1) RU2760521C2 (enExample)
WO (1) WO2018059896A1 (enExample)
ZA (1) ZA201902388B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
WO2020252039A1 (en) * 2019-06-12 2020-12-17 Biontech Us Inc. Neoantigen compositions and uses thereof
US20220305099A1 (en) * 2019-08-27 2022-09-29 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257286C (zh) 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
CN100352921C (zh) 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2005060541A2 (en) 2003-12-01 2005-07-07 Wisconsin Alumni Research Foundation Peptides and methods for inducing cellular resistance to infection
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
NO2700405T3 (enExample) * 2008-05-29 2018-09-01
EP2349296B1 (en) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
US8609392B2 (en) * 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
BR112016009465A8 (pt) * 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
US10799568B2 (en) 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING，2015年06月，VOL:112, NR:6，PAGE(S):1102 - 1110，http://dx.doi.org/10.1002/bit.25537

Also Published As

Publication number Publication date
NZ751251A (en) 2025-03-28
AU2017337753A1 (en) 2019-03-21
JP2019532631A (ja) 2019-11-14
JP2023029997A (ja) 2023-03-07
KR102599401B1 (ko) 2023-11-06
US10982194B2 (en) 2021-04-20
AU2023237201A1 (en) 2023-12-14
AU2017337753B2 (en) 2023-09-28
US20200010811A1 (en) 2020-01-09
RU2019110407A (ru) 2020-10-29
EP3519565A1 (en) 2019-08-07
RU2760521C2 (ru) 2021-11-26
BR112019005825A2 (pt) 2019-06-11
GB201616365D0 (en) 2016-11-09
ZA201902388B (en) 2020-10-28
WO2018059896A1 (en) 2018-04-05
AU2023237201B2 (en) 2025-06-05
CN109890957A (zh) 2019-06-14
CA3035104A1 (en) 2018-04-05
RU2019110407A3 (enExample) 2021-05-13
KR20190053260A (ko) 2019-05-17

Similar Documents

Publication Publication Date Title
JP2023029997A (ja) エンベロープウイルスの非遺伝的改変
Hamley Peptides for vaccine development
AU2017234192B2 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
Krauss et al. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody
KR100457647B1 (ko) 펩티드및애쥬번트에기초한면역조절용약제학적조성물
CN107050440B (zh) 疫苗组合物和其使用方法
Cruz et al. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN
US20250312428A1 (en) Heterologous Prime Boost Vaccine
US10925960B2 (en) Antigen delivery system
RS65262B1 (sr) Antigenski peptidi za prevenciju i lečenje maligniteta b ćelija
Kim et al. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells
JP2023543554A (ja) 修飾マイコバクテリウム・ボビス・ワクチン
CN109758575B (zh) 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
Maxwell et al. Intranasal self-adjuvanted lipopeptide vaccines elicit high antibody titers and strong cellular responses against SARS-CoV-2
WO2022235678A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
RU2843609C1 (ru) Вакцины модифицированных Mycobacterium Bovis
EP3055322B1 (en) Ubiquitinylated proteins
CN120789242A (zh) 一种egfr l858r突变特异性长肽疫苗及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230104

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250